Cargando…

IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiagarajan, Divya, Oparina, Nina, Lundström, Susanna, Zubarev, Roman, Sun, Jitong, Alarcon-Riquelme, Marta, Frostegård, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335044/
https://www.ncbi.nlm.nih.gov/pubmed/32620913
http://dx.doi.org/10.1038/s41598-020-66981-z
_version_ 1783554056833204224
author Thiagarajan, Divya
Oparina, Nina
Lundström, Susanna
Zubarev, Roman
Sun, Jitong
Alarcon-Riquelme, Marta
Frostegård, Johan
author_facet Thiagarajan, Divya
Oparina, Nina
Lundström, Susanna
Zubarev, Roman
Sun, Jitong
Alarcon-Riquelme, Marta
Frostegård, Johan
author_sort Thiagarajan, Divya
collection PubMed
description IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.
format Online
Article
Text
id pubmed-7335044
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73350442020-07-07 IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases Thiagarajan, Divya Oparina, Nina Lundström, Susanna Zubarev, Roman Sun, Jitong Alarcon-Riquelme, Marta Frostegård, Johan Sci Rep Article IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions. Nature Publishing Group UK 2020-07-03 /pmc/articles/PMC7335044/ /pubmed/32620913 http://dx.doi.org/10.1038/s41598-020-66981-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Thiagarajan, Divya
Oparina, Nina
Lundström, Susanna
Zubarev, Roman
Sun, Jitong
Alarcon-Riquelme, Marta
Frostegård, Johan
IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title_full IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title_fullStr IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title_full_unstemmed IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title_short IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
title_sort igm antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335044/
https://www.ncbi.nlm.nih.gov/pubmed/32620913
http://dx.doi.org/10.1038/s41598-020-66981-z
work_keys_str_mv AT thiagarajandivya igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT oparinanina igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT lundstromsusanna igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT zubarevroman igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT sunjitong igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT alarconriquelmemarta igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases
AT frostegardjohan igmantibodiesagainstmalondialdehydeandphosphorylcholineindifferentsystemicrheumaticdiseases